Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.1119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Taiping He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Biomarkers, Tumor, Coenzyme A Ligases, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Collaborative innovation project of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Purpose
Investigate the role of lipid metabolism in the tumor immune microenvironment (TIME) of lung adenocarcinoma (LUAD) and identify vital lipid metabolism-related genes (LMRGs) that contribute to immunotherapy outcomes.Materials and Methods One thousand one hundred thirty LUAD patients were acquired utilizing public databases. Multiple algorithms were used to analyze the contribution of lipid metabolism in TIME. Importantly, cell lines, clinical samples (52 patients in surgery cohort and 36 in immunotherapy cohort), animal models, RNA sequencing (RNA-seq), experiments in protein and mRNA levels were conducted for identifying and validating key biomarker in LUAD immunotherapy.
Results
A prognostic signature comprising 33 LMRGs was developed and validated as an effective predictor of prognosis and TIME, with a C-index of 0.766 (95% confidence interval, 0.729 to 0.804). Additionally, we identified acyl-CoA synthetase long-chain family member 3 (ACSL3) as a potential biomarker for immunotherapy prognosis. The expression of ACSL3 was verified in 88 clinical tissues from LUAD patients, which indicated that elevated ACSL3 expression was correlated with worse progression-free survival (p < 0.001) and overall survival (p=0.008). Subsequent experiments revealed that knockdown of ACSL3 in vivo enhanced the efficacy of immunotherapy, potentially through increasing interferon-α secretion, as indicated by bulk RNA-seq and enzyme-linked immunosorbent assay analysis, thereby promoting the infiltration of antitumor immune cells.
Conclusion
The study established a model that accurately predicts immunotherapy response, prognosis, and TIME dynamics in LUAD patients. Notably, the pivotal role of ACSL3 in driving tumor progression and immune evasion was uncovered, offering novel insights into the optimization of immunotherapy strategies for LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
- Bengbu Medical University, School of Nursing Bengbu, Bengbu, China.
- Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Collaborative innovation project of Shanghai Municipal Health Commission
Zitieren
APA
He, T., Hu, J., Guo, H., Diao, M., Wang, Y., Wu, Y., Cheng, L., Zhao, C., Li, X., & Zhou, C. (2025). Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.1119
Vancouver
He T, Hu J, Guo H, Diao M, Wang Y, Wu Y, et al. Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.1119
BibTeX
@article{He2025,
author = {He, Taiping and Hu, Jinhan and Guo, Haoyue and Diao, Meng and Wang, Yuanyuan and Wu, Yuhan and Cheng, Lei and Zhao, Chao and Li, Xuefei and Zhou, Caicun},
title = {Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.1119}
}
EUVIMED